Učitavanje...
Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer’s disease therapy
Nowadays, Alzheimer’s disease (AD) is widely recognized as a real social problem. In fact, only five drugs are FDA approved for the therapy of this widespread neurodegenerative disease, but with low results so far. Three of them (rivastigmine, donepezil and galantamine) are acetylcholinesterase inhi...
Spremljeno u:
| Izdano u: | Neural Regen Res |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Medknow Publications & Media Pvt Ltd
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5607816/ https://ncbi.nlm.nih.gov/pubmed/28966636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1673-5374.213541 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|